IRIS UniCatt

Pugliese, Daniela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.775
AS - Asia 2.329
EU - Europa 2.146
SA - Sud America 657
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 7.992
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.667
SG - Singapore 1.109
DE - Germania 590
BR - Brasile 537
CN - Cina 536
SE - Svezia 387
IT - Italia 294
FR - Francia 194
VN - Vietnam 187
GB - Regno Unito 148
IE - Irlanda 113
IN - India 111
UA - Ucraina 95
ID - Indonesia 94
FI - Finlandia 91
CA - Canada 64
AR - Argentina 52
RU - Federazione Russa 52
PL - Polonia 49
KR - Corea 39
HK - Hong Kong 37
BD - Bangladesh 36
TR - Turchia 35
MX - Messico 31
ES - Italia 29
JP - Giappone 26
IQ - Iraq 24
AT - Austria 22
NL - Olanda 22
EC - Ecuador 21
ZA - Sudafrica 21
BE - Belgio 15
CO - Colombia 15
CI - Costa d'Avorio 12
IR - Iran 11
SA - Arabia Saudita 11
CZ - Repubblica Ceca 10
IL - Israele 10
MA - Marocco 10
UZ - Uzbekistan 10
VE - Venezuela 10
EG - Egitto 9
PK - Pakistan 8
UY - Uruguay 8
DZ - Algeria 7
JO - Giordania 7
KE - Kenya 7
PH - Filippine 7
AE - Emirati Arabi Uniti 6
JM - Giamaica 6
TN - Tunisia 6
CH - Svizzera 5
HU - Ungheria 5
AL - Albania 4
BG - Bulgaria 4
LT - Lituania 4
PE - Perù 4
AZ - Azerbaigian 3
CL - Cile 3
KZ - Kazakistan 3
NP - Nepal 3
OM - Oman 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CR - Costa Rica 2
GA - Gabon 2
HN - Honduras 2
LB - Libano 2
LV - Lettonia 2
PT - Portogallo 2
RO - Romania 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EE - Estonia 1
ET - Etiopia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
KG - Kirghizistan 1
KW - Kuwait 1
MD - Moldavia 1
ML - Mali 1
MM - Myanmar 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
QA - Qatar 1
SC - Seychelles 1
SN - Senegal 1
SR - Suriname 1
Totale 7.991
Salva come PNG Salva come JPEG
Città #
Singapore 556
Chandler 451
Ashburn 310
Beijing 153
New York 138
Los Angeles 114
Dublin 109
Hefei 86
Jacksonville 77
Jakarta 75
Munich 65
Ho Chi Minh City 64
San Mateo 61
Dearborn 54
Rome 54
Milan 49
The Dalles 49
Frankfurt am Main 46
Boston 45
Ann Arbor 44
Cattolica 43
São Paulo 43
Seoul 39
Hanoi 38
Houston 35
Warsaw 35
Hong Kong 34
Princeton 34
Wilmington 33
Moscow 30
Nürnberg 30
Helsinki 29
Nanjing 29
Chicago 27
Hyderabad 27
Marseille 27
Dallas 25
Bremen 23
Kent 23
Montreal 23
Turku 23
Tokyo 22
Denver 21
Seattle 21
Lappeenranta 20
Nuremberg 19
Stockholm 19
Boardman 18
Brooklyn 18
London 18
Toronto 18
Chennai 17
Düsseldorf 17
Lawrence 17
Belo Horizonte 15
Brussels 15
Buffalo 15
Fairfield 15
Lancaster 15
Detroit 14
Redwood City 14
Johannesburg 13
Rio de Janeiro 13
Abidjan 12
Baghdad 12
Falkenstein 12
Poplar 12
Shenyang 12
Atlanta 11
Izmir 11
North Bergen 11
Orem 11
Augusta 10
Brasília 10
Cagliari 10
Curitiba 10
Haiphong 10
Leawood 10
Manchester 10
Mexico City 10
Nanchang 10
San Francisco 10
Woodbridge 10
Ankara 9
Dhaka 9
Quito 9
Santa Clara 9
Vienna 9
Council Bluffs 8
Lauterbourg 8
Montevideo 8
Paris 8
Portsmouth 8
Tashkent 8
Washington 8
Amman 7
Amsterdam 7
Bogotá 7
Calgary 7
Jiaxing 7
Totale 3.974
Salva come PNG Salva come JPEG
Nome #
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 191
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 186
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 180
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 176
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 174
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 173
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 156
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 152
Ileal Crohn's disease: CEUS determination of activity 144
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 141
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 141
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 136
Challenges in crohn’s disease management after gastrointestinal cancer diagnosis 135
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study 128
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 123
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 118
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 116
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 115
Transition from intravenous to subcutaneous biological therapies in inflammatory bowel disease: An online survey of patients 113
Management of perianal fistulas in Crohn's disease: an up-to-date review 112
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 109
Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease 108
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 103
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 101
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 101
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 98
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 96
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study. 96
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 95
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 95
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 95
Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis 94
Crohn's Disease: Radiological Answers to Clinical Questions and Review of the Literature 94
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 92
Radiomics could predict surgery at 10 years in Crohn's disease 91
Serial Fecal Microbiota Infusions via Colonoscopy for Active Ulcerative Colitis: A Feasibility, Safety, and Translational Monocentric Italian Study 91
Combination therapy in inflammatory bowel disease – from traditional immunosuppressors towards the new paradigm of dual targeted therapy 91
Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease 90
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 89
Histologic Disease Persists beyond Mucosal Healing and Could Predict Reactivation in Ulcerative Colitis 88
Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study 87
Adalimumab in active ulcerative colitis: a "real-life" observational study 87
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 87
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 87
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study 87
Novel Insights into the Pathogenesis of Inflammatory Bowel Diseases 85
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: A case report 84
Frontiers in drug research and development for inflammatory bowel disease 83
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 83
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG‐IBD LIVE study 80
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 80
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 79
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 79
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study 78
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study 78
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 78
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 78
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 76
SARS-CoV-2 infection in patients with inflammatory bowel disease: comparison between the first and second pandemic waves 74
Rates of Adverse Events in Patients With Ulcerative Colitis Undergoing Colectomy During Treatment With Tofacitinib vs Biologics: A Multicenter Observational Study 74
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 74
Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab 73
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 73
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study 72
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study 71
Clinical, Radiological, and Surgical Risk Factors for Endoscopic Anastomotic Recurrence Following Surgery in Crohn's Disease 71
Orphan patients with inflammatory bowel disease - when we treat beyond evidence 71
Long-term safety of in utero exposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study 70
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 69
Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy 67
The thrilling journey of sars-cov-2 into the intestine: From pathogenesis to future clinical implications 67
Replacement of Adalimumab Originator to Adalimumab Biosimilar for a Non-Medical Reason in Patients with Inflammatory Bowel Disease: A Real-life Comparison of Adalimumab Biosimilars Currently Available in Italy 66
Diet and nutrients in gastrointestinal chronic diseases 65
PragmaticTrial Design to Compare Real-world Effectiveness of DifferentTreatments for Inflammatory Bowel Diseases:The PRACTICE-IBD European Consensus 63
Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study 60
The inflammatory bowel disease care manager: Italian state of the art 59
Patient-Reported Outcomes for the Assessment of Sexual Health Among Patients Affected by Inflammatory Bowel Disease 59
The educational role of IBD nurses in Italy in vaccinations: do not miss the moment for COVID-19 59
Effectiveness and Safety of Switching from Intravenous to Subcutaneous Vedolizumab Formulation in Inflammatory Bowel Disease Patients in Clinical Remission 59
Effectiveness of autologous emulsified stromal vascular fraction tissue injection for the treatment of complex perianal fistulas in inflammatory bowel diseases patients: a pilot study 57
Reply to managing patients with ulcerative colitis with infliximab in primary and referral gastroenterology centers 57
Challenges in Crohn's Disease Management after Gastrointestinal Cancer Diagnosis 56
Nonmedical switch of anti-TNF-α biosimilars has no major clinical, pharmacokinetic and psychological impact on patients with IBD - the SAFER Study 55
Morbidly Obese Patient With Ulcerative Colitis Treated With Endoscopic Gastroplasty: A Case Report 51
Adaptation of the European Crohn's Colitis Organisation quality of care standards to Italy: The Italian Group for the study of inflammatory bowel disease consensus 49
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 48
Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study 27
Totale 8.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.030
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.030
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021155 0 0 0 0 0 14 16 10 32 10 62 11
2021/2022458 37 19 8 70 8 10 10 65 9 25 90 107
2022/20231.127 148 147 78 182 71 130 54 103 143 15 36 20
2023/2024767 18 161 30 72 23 126 45 48 41 39 72 92
2024/20251.734 20 43 137 30 129 65 133 84 207 217 365 304
2025/20262.805 687 236 331 631 752 168 0 0 0 0 0 0
Totale 8.119